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A B S T R A C T   
The biodynamics and biokinetics of sex hormones are complex. In addition to the classical steroid receptors 
(nuclear receptors), these hormones act through several non-genomic mechanisms. Modulation of ABC- 
transporters by progesterone represents a non-genomic mechanism. In the present study, we employed inside 
out vesicles from human erythrocytes to characterize high affinity cGMP transport by ABCC5 (member 5 of the 
ATP-Binding Cassette subfamily C). Progesterone and testosterone inhibited the transport with respective Ki of 
1.2 ± 0.3 and 2.0 ± 0.6 μmol/L. We used virtual ligand screening (VLS) to identify analogues to progesterone and 
testosterone. A large number of substances were screened in silico and the 19 most promising candidates were 
screened in vitro. Each substance was tested for a concentration of 10 μmol/L. The range of cGMP transport 
reduction was 21.5% to 86.2% for progesterone analogues and 8.6% to 93.8 % for testosterone analogues. Three 
of the most potent test compounds (TC) of each analogue class, in addition to progesterone and testosterone, 
were characterized for concentrations from 1 nanomol/L to 1 mmol/L. The progesterone analogues showed 
following Ki-values (μmol/L): TC-08: 0.61, TC-16: 0.66 and TC-15: 9.3. The Ki-values (μmol/L) for the testos-
terone analogues were: TC-18: 0.10, TC-07: 0.67 andTC-05: 2.0. The present study shows that VLS may be a 
versatile tool in the development of membrane transport modulating agents (MTMAs).   
1. Introduction 
According to the free hormone hypothesis, the lipophilic character of 
the steroid hormones enables the unbound fraction to enter target cells 
by passive diffusion. However, it has been suggested [1] that the bound 
fraction of steroids, and especially conjugated steroids, might utilize 
transmembrane SLC- carriers for cellular uptake. The SLCO transporter 
superfamily includes 11 human SLCOs [2]. The SLCOs have transport 
characteristic compatible with active transport, but the mechanisms are 
not known in detail, but evidence for an anion-exchange transport exists 
[2]. Members of the SLC22-family are also involved in cellular uptake of 
endogenous organic anions [3]. Both transporter affinities for substrates 
and cellular transporter expression are determinative for the respective 
specificity and tissue selectivity. 
In addition to passive cellular efflux, primary active pumps such as 
ABC-transporters contribute to cellular uptake and efflux of steroids. 
Progesterone is a substrate for ABCB1 with slow transport [4] and 
responsible for the reversal of multidrug resisteance (MDR) [5]. Pro-
gesterone reduced cGMP efflux from intact HEK293 cells overexpressing 
ABCC4 [6]. The observation that testosterone levels in some of the 
seminiferous tubules of the testis may reach approximately 100 times 
the levels in the systemic circulation [7] is consistent with active 
transport. ABCC1 and ABCG2 are expressed at the luminal side of testis 
capillaries, whereas Sertoli cells mainly express ABCB1, ABCC1 and 
ABCC4 [8–10]. These transporters are important for the blood testis 
barrier (BTB) since they protect he male reproductive system against 
toxic xenobiotics [11]. 
We have previously reported that progesterone inhibits cGMP efflux 
by ABCC5 [12,13] (for reference [13], see note in Addendum) with high 
affinity (Ki: 1.7–2.2 μmol/L). This is a non-genomic effect of proges-
terone, in addition to several others [14,15]. As far as we know, the 
interaction between testosterone and ABCC5 has not been reported 
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before. In the present study, analogues of progesterone and testosterone 
were identified with molecular modeling and virtual ligand screening 
(VLS), and their effects on ABCC5-mediated cGMP transport were 
characterized in vitro. 
2. Materials and methods 
2.1. Software 
The ICM program [16], version 3.6− 1, was used for homology 
modeling, compound docking and substructure search. The program 
package included the ICM VLS add-on and access to Molcart, a database 
of chemical structures for approximately 40000 commercially available 
compounds. 
2.2. Homology modeling and virtual ligand screening (VLS) 
A homology model of ABCC5 [17] was used for the present study. 
The methods employed in the s present work are described in a recent 
publication [18]. Energy-based torsional sampling was used to generate 
additional conformations of the ligand binding area of ABCC5 to 
investigate putative ligand binding modes in the highly flexible trans-
porter protein. This computational technique generates more "drug 
gable" conformations of ligand binding pockets [19]. 
The putative analogues of progesterone and testosterone were 
identified with the ICM VLS technology, which provides excellent tools 
for accurate individual ligand-protein docking. Table 1 shows the 
compounds with a potential to modulate ABCC5 transport. The sub-
stances were synthesized and purchased from Pharmeks Interbioscreen 
(Institutsky Prospect, Chernogolovka, Russia). 
2.3. Preparation of inside-out vesicles (IOVs) and transport assay 
The isolation and lysis of human erythrocytes, vesicle formation, 
ghost membranes and separation of IOVs from both right-side-out ves-
icles and ghosts, were performed essentially as described previously 
[20]. The sidedness in the fraction containing IOVs was verified using 
acetylcholinesterase accessibility [21,22]. 
2.4. Transport assay 
The procedure employed for transport studies has been described in 
detail earlier [20]. The uptake of [3H]-cGMP (2 μmol/L) to IOVs was 
terminated after 60 min incubation at37◦. The difference between total 
transport (with 2 mmol/L Mg2+-ATP) and non-specific transport 
(without 2 mmol/L Mg2+-ATP) represents the specific transport of 
cGMP. In the inhibition studies, progesterone, testosterone and their 
putative analogues, in addition to sildenafil, were present in concen-
trations from 1 nanomol/Lto1 mmol/L. 
Comparison of two different ultrafiltration methods showed virtually 
identical results. In the first assay, a 12-well manifold was employed 
[20]. The second assay involved 96-well incubation-plates and mani-
folds. [3H]-cGMP, Mg2+-ATP, steroid analogues, potassium- phosphate 
buffered saline (pH 8.1) and IOVs were added to the wells with the plates 
placed on wet ice (0− 4◦). After centrifugation for 30 s at 200 g (Omni-
fuge, 2.0 RS, Heraeus Sepatech, Germany), the plates were incubated for 
60 min in a water bath at 37◦. The transport was terminated by placing 
the plates on wet ice. Prior to the filtration, the filter paper (nitrocel-
lulose membrane sheet 0.2 μm, Bio-Rad Laboratories, Germany) was 
soaked in potassium-phosphate buffered saline before assembly of the 
manifold. After filtration, the filters were washed with ice-cold potas-
sium-phosphate buffered saline and dried for 20 min at 30◦. Each well 
with the dried filter, was added 30 μL scintillation fluid (MicroScint, 
Perkin Elmer, Waltham, MA, USA). The radioactivity was quantified by 
scintillation counting using a Packard TopCount NXT (Packard, 
Downers Grove, IL, USA). 
Table 1 
Putative ABCC5 inhibitors (TC-01- TC-19) from the VLS procedure that were 
ordered from Interbioscreen (Institutsky Prospect, 7a, 142432 Chernogolovka, 
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2.5. Analysis of experimental data 
IC50-values were obtained according to Chou [23] and Ki-values 
calculated according to Cheng and Prusoff [24], using substrate con-
centration (2 μmol/L cGMP) and the Km-value (2.7 μmol/L) for cGMP, 
obtained under similar experimental conditions [20]. 
3. Results 
3.1. Virtual ligand screening (VLS) 
The in silico screening identified 19 putative analogues (Table 1). 
Some of these substances were characterized as analogues to proges-
terone and some to testosterone (Table 2). In the present study, the 
docking score (ICM) obtained for the interaction between the analogues 
and the ABCC5 binding site, ranged from -33.57 to -38.35. The drug 
likeness ranged from -0.0377 to 1.4982. 
3.2. Pharmacological screening 
The in vitro screening was performed with the 19 compounds shown 
in Table 2. Their ability to inhibit high affinity [3H]-cGMP and ATP- 
dependent transport, was tested with 10 μmol/L analogue. Table 2 
shows that the reduction was 21.5–86.2 % for progesterone analogues 
and 8.6–93.8 % for testosterone analogues. The most potent inhibitors 
(n = 6) showed orders of potency for the progesterone analogues: TC-08 
≥ TC-16 > TC-15 and for the testosterone analogues: TC-07 > TC-18 >
TC-05. 
3.3. Concentration-dependent inhibition 
The IC50-values were obtained from the concentration-dependent 
inhibition curves (Fig. 1) and the Ki-values calculated as described in 
the methods. Sildenafil was used as positive control for inhibition of 
cGMP efflux. The IC50- and Ki- values for sildenafil, obtained in the 
present stud were 4.72 ± 0.39 and 2.67 ± 0.22 μmol/L, respectively. 
Progesterone and testosterone were employed as reference inhibitors for 
their respective analogues. Table 3 shows that progesterone and 
testosterone were nearly equipotent. The orders of inhibitory potency 
for progesterone and for testosterone analogues were TC-08 ≥ TC-16 >
> TC-15 and TC-07 > TC-18 > TC-05, respectively. 
4. Discussion 
The present study has focused on the inhibition of ABC5-mediated 
transport of cGMP by progesterone, testosterone and their analogues. 
ABCC5, which is ubiquitously expressed, and localized to the basolateral 
membrane of some polarized epithelial cells and to the apical membrane 
in others, such as the brain capillary endothelial cells. ABCC5, like 
ABCC4, is capable of dual-membrane localization [24]. The ABCC5 
expression is high in some tissues (i.e. cardiac and smooth vascular 
muscles) and in some organs (i.e. brain and kidney) [25]. In the IOV 
model with human erythrocytes, the ABCC5-mediated cGMP transport 
was composed of one high and a second low affinity component [26]. 
This transport system was identified as ABCC5 [27], and verified by 
others [28,29]. The reduction of ABCC5 membrane concentration par-
alleled a marked lowering of cGMP transport in proteoliposomes [30] 
and in pituitary GH3 cells after silencing ABCC5 [31]. In the last 
mentioned study, the cAMP transport was unperturbed. The authors 
suggested that two pumps existed for cyclic nucleotides in pituitary cells 
and that that ABCC5 operated as a cGMP-selective transporter. 
In traditional biochemical experiments, we showed that 100 μmol/L 
cAMP reduced the high affinity transport of cGMP with only 15 % [12]. 
In a more recent study [20], a steep fall in cGMP transport was seen for 
cAMP concentrations from100 to 1000 μmol/L. This gave an estimated 
IC50-value of 695 μmol/L. We have proposed that ABCC5 has a specific 
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Table 2 
Progesterone (P) and testosterone (T)analogues – VLS-results on drug likeness, 
docking (ICM-score) and screening of test compounds (TC) 1 – 19 for their ability 
(in a concentration of 10 μM) to inhibit ATP-dependent [3H]-cGMP uptake to 
hRBC IOVs. Three time independent series in duplicate (Mean ± SD).  
Test compound 
codes 







TC-01 (#423) 1.26268 − 34.0394 P 82.5 ± 6.5 
TC-08 (#430) 1.08898 35.5277 P 21.5 ± 6.6 * 
TC-09 (#431) 1.37145 − 35.7915 P 43.1 ± 7.6 
TC-10 (#432) 1.29281 − 34.5299 P 86.2 ± 5.9 
TC-11 (#433) 1.43892 − 34.7817 P 77.2 ± 5.3 
TC-12 (#434) 1.29676 − 35.4267 P 76.7 ± 4.9 
TC-13 (#435) 0.25981 − 35.9009 P 75.7 ± 11.7 
TC-14 (#436) 1.02529 − 37.4281 P 56.5 ± 5.4 
TC-15 (#437) 1.49841 − 38.3509 P 41.0 ± 5.1 * 
TC-16 (#438) 0.382176 − 38.7701 P 23.7 ± 4.6 * 
TC-17 (#439) 1.02194 − 41.3668 P 71.5 ± 5.4 
TC-19 (#441) 0.424506 − 39.5453 P 56.5 ± 8.1 
TC-02 (#424) 1.18021 − 33.277 T 79.4 ± 2.6 
TC-03 (#425) 1.18277 − 33.5606 T 58.9 ± 5.5 
TC-04 (#426) 1.37079 − 33.5668 T 45.4 ± 10.0 
TC-05 (#427) 0.981743 − 33.9976 T 38.3 ± 7.0 * 
TC-06 (#428) 1.02383 34.1923 T 93.8 ± 7.3 
TC-07 (#429) 0.981427 − 34.2954 T 25.9 ± 4.8 * 
TC-18 (#440) − 0.0376617 − 36.5219 T 8.6 ± 2.9 *  
* Analogues used for concentration effect studies. 
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high affinity site for cGMP and a second common nonspecific low af-
finity site for the two cyclic nucleotides [32]. 
The present study of specific high affinity cGMP transport, showed 
similar progesterone Ki-value as those reported before with the IOV 
model [12,13]. Progesterone modulation of ABCC5 transport extends 
the list of non-genomic effects [15]. Two of the analogues (TC-08 and 
TC-16) were clearly more potent than progesterone whereas the third 
(TC-15) was much less potent. The present results extend our experience 
with VLS as a valuable tool for predicting putative drugs such as ana-
logues to sildenafil [17] and vardenafil [18]. 
Modern male reproductive physiology (androgenesis and physi-
ology) started with the discovery and synthesis of testosterone [33]. 
However, the impact of testosterone on clinical condition like metabolic 
syndrome and type-2 diabetes has received much attention in the recent 
years [34]. Furthermore, the role of testosterone for female health, bone 
and muscle physiology, mood disorders and cognitive health have also 
come into focus [35]. 
Testosterone inhibited ABCC5 transport with a similar Ki-value as 
progesterone. As far as we know, no previous report of ABCC5-mediated 
transport of testosterone exists. It is likely that testosterone is a slow 
moving substrate for ABCC5 as progesterone is for ABCB1 [4]. ABCC5 
has low expression in human specialized testicular tissues [25], but is 
present in the testicular vascular smooth muscle cells. 
The effect of sildenafil on erectile dysfunction was initially only 
ascribed to the inhibition of PDE5 [36]. However, the observation that 
sildenafil inhibited ABCC5-mediated cGMP efflux [27], made the 
cellular pharmacodynamics of sildenafil more complex. Since ABCC5 is 
highly expressed in corpus cavernous [37], testosterone (Ki ≈ 2.0 
μmol/L) may have a sildenafil-like effect (Ki ≈ 2.7 μmol/L) on cellular 
extrusion of cGMP. With a focus on this non-genome action, the two 
testosterone analogues TC-07 (Ki ≈ 0.7 μmol/L) and TC-18 (Ki ≈ 0.1 
μmol/L), would be markedly more potent than sildenafil. Progesterone, 
testosterone and their analogues should also be tested for their ability to 
inhibit PDE5in order to clarify their pharmacodynamics roles. 
Nongenomic testosterone effects by other ABC-transporters have 
been firmly documented in adult human testis. Leydig cells express 
ABCB1, ABCC1 and ABCC4 [38,39]. ABCB1 and ABCG2 are present at 
the luminal side of testis capillaries, whereas Sertoli cells mainly express 
ABCB1, ABCC1 and ABCC4 [8–10]. The present study shows an addi-
tional non-genomic effect of testosterone. 
Serum protein binding has an important regulatory role in the steroid 
action [40]. The free hormone hypothesis implies that only the unbound 
fractions of steroids are available for cellular uptake. This idea is too 
simplistic [41]. The observations that progesterone and /or testosterone 
are substrates for the active membrane pumps like ABCB1 [5,9], ABCC4 
[6], ABCC5 [6,13] plus the present work, and ABCG2 [9]. These trans-
porters make it possible for both unbound and bound hormone to enter 
tissues and cells. In clinical pharmacokinetics, this corresponds to sub-
stances defined as high extraction drugs. Such transport is characterized 
by high extraction, and depends on the rate of substrate presentation 
and not the extent of protein binding [42]. 
Members of the SLC-families are identified as transporters for me-
tabolites of progesterone and testosterone, for review [43].This is of 
special interest in tissues with peripheral metabolism (other than liver 
tissue) [35] because biotransformation reduces concentrations of pro-
gesterone and testosterone and thereby facilitate transport by the 
gradient that occurs. 
In this study, we have employed a cell model (hRBC IOVs) to char-
acterize interaction between ABCC5 and hormones (progesterone and 
testosterone) in addition to analogues of these hormones (putative 
therapeutic agents). However, future studies with primary cell models 
such as known target cells for progesterone and testosterone, are needed 
to extend the scientific impact in biomedicine and clinical medicine. The 
interaction between the analogues and nuclear receptors [44,45] in 
addition to non-genomic mechanisms such as membrane receptors [15, 
46], should also be characterized in future studies. 
5. Addendum 
We regret having overlooked errors in Table 2 [13] during proof 
reading. The correct Ki-values are 1.7 ± 0.5 μmol/L and 26 ± 14 μmol/L 
for progesterone and megestrol acetate, respectively. 
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Fig. 1. Active transport of [3H]-cGMP in presence of progesterone and ana-
logues (panel A) and testosterone and analogues (Panel B). The results are 
presented as mean ± SD (n = 3). Panel A: Progesterone (●), TC-08 / #430 (▴), 
TC-15 (▾), TC-16 (◼). Panel B: Testosterone (●), TC-05 (▴) TC-07 (▾), TC- 
18 (◼). 
Table 3 
IC50- and Ki-values of progesterone analogues (P) and testosterone analogues (T) 
for their inhibition of ATP-dependent [3H]-cGMP high affinity uptake to hRBC 
IOVs. Progesterone and testosterone were employed as reference substances. 
The numbers represent three time-independent series in duplicate (Mean ± SD).  
Compound Analogue to IC50 (μmol/L) Ki (μmol/L) 
Progesterone – 2.16 ±0.59 1.22 ± 0.34 
TC-08 (#430) P 1.09 ±0.09 0.61 ±0.05 
TC-15(#437) P 16.4 ± 2.63 9.28 ±1.48 
TC-16 (#438) P 1.17 ± 0.30 0.66 ± 0.17 
Testosterone – 3.50 ± 1.12 1.97 ± 0.63 
TC-05 (#427) T 3.57 ± 0.82 2.02 ± 0.46 
TC-07 (#429) T 1.19 ± 0.082 0.672 ± 0.046 
TC-18 (#440) T 0.177 ± 0.016 0.100 ± 0.009  
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